Hepatitis E vaccine-Illuminating the barriers to use

Affiliations

¹ International Vaccine Institute, Seoul, Korea.
² Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
³ National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria.
⁴ Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
⁵ Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
⁶ Department of Public Health, Syracuse University, Syracuse, New York, United States of America.
⁷ Department of Gastroenterology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
⁸ Médecins sans Frontières, Geneva, Switzerland.
⁹ Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.

Julia A Lynch et al. PLoS Negl Trop Dis. 2023.

. 2023 Jan 5;17(1):e0010969.

doi: 10.1371/journal.pntd.0010969. eCollection 2023 Jan.

¹ International Vaccine Institute, Seoul, Korea.
² Department of Immunization, Vaccines and Biologicals, World Health Organization, Geneva, Switzerland.
³ National Agency for Food and Drug Administration and Control (NAFDAC), Nigeria.
⁴ Wits RHI, University of the Witwatersrand, Johannesburg, South Africa.
⁵ Department of International Health, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.
⁶ Department of Public Health, Syracuse University, Syracuse, New York, United States of America.
⁷ Department of Gastroenterology, Jawaharlal Institute of Postgraduate Medical Education and Research, Puducherry, India.
⁸ Médecins sans Frontières, Geneva, Switzerland.
⁹ Department of Epidemiology, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland, United States of America.

No abstract available

Conflict of interest statement

The authors have declared that no competing interests exist.

1. Li P, Liu J, Li Y, Su J, Ma Z, Bramer WM, et al.. The global epidemiology of hepatitis E virus infection: A systematic review and meta-analysis. Liver Int. 2020;40(7):1516–28. Epub 2020 Apr 24. doi: 10.1111/liv.14468 PMCID: PMC7384095. . - DOI - PMC - PubMed
1. Rein DB, Stevens GA, Theaker J, Wittenborn JS, Wiersma ST. The global burden of hepatitis E virus genotypes 1 and 2 in 2005. Hepatology. 2012;55(4):988–97. doi: 10.1002/hep.25505 PMCID: . - DOI - PubMed
1. Okagbue HI, Adamu MO, Bishop SA, Oguntunde PE, Odetunmibi OA, Opanuga AA. Hepatitis E Infection in Nigeria: A Systematic Review. Open Access Maced J Med Sci. 2019;7(10):1719–22. Epub 2019 May 29. doi: 10.3889/oamjms.2019.143 PMCID: PMC6560297. . - DOI - PMC - PubMed
1. Smith JL. A review of hepatitis E virus. J Food Prot. 2001;64(4):572–86. doi: 10.4315/0362-028x-64.4.572 . - DOI - PubMed
1. Primadharsini PP, Nagashima S, Okamoto H. Genetic Variability and Evolution of Hepatitis E Virus. Viruses. 2019;11(5):456. doi: 10.3390/v11050456 . PMCID: PMC6563261. - DOI - PMC - PubMed